Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2016

Haas T, Spielmann N, Restin T, Schmidt AR, Schmugge M, Cushing MM. Economic aspects of intraoperative coagulation management targeting higher fibrinogen concentrations during major craniosynostosis surgery. Paediatr Anaesth. 2016;26(1):77-83.

D'Alfonso TM, Subramaniyam S, Ginter PS, Mosquera JM, MacDonald TY, Noorzad Z, et al. Characterization of the leiomyomatous variant of myofibroblastoma: a rare subset distinct from other smooth muscle tumors of the breast. Hum Pathol. 2016;58:54-61.

Wang SA, Tam W, Tsai AG, Arber DA, Hasserjian RP, Geyer JT, et al. Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Mod Pathol. 2016;29(8):854-64.

Marin EP, József L, Di Lorenzo A, Held KF, Luciano AK, Melendez J, et al. The Protein Acyl Transferase ZDHHC21 Modulates α1 Adrenergic Receptor Function and Regulates Hemodynamics. Arterioscler Thromb Vasc Biol. 2016;36(2):370-9.

Lee SS, Tyler JK. Physiology: Stressed-out chromatin promotes longevity. Nature. 2016;534(7609):625-6.

Yi J, Humphries R, Doerr L, Jerris RC, Westblade LF. Bergeyella zoohelcum Associated with Abscess and Cellulitis After a Dog Bite. Pediatr Infect Dis J. 2016;35(2):214-6.

Staunton L, Tonry C, Lis R, Finn S, Leary JO, Loda M, et al. Profiling the tumor microenvironment proteome in prostate cancer using laser capture microdissection coupled to LC⿿MS⿿A technical report. EuPA Open Proteom. 2016;10:19-23.

Reid MD, Basturk O, Shaib WL, Xue Y, Balci S, Choi H-, et al. Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: an analysis of 77 cases. Mod Pathol. 2016;29(10):1243-53.

Hsu Y-, Cushing MM. Autologous Stem Cell Mobilization and Collection. Hematol Oncol Clin North Am. 2016;30(3):573-89.

Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, et al. MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clin Cancer Res. 2016;22(4):935-47.